Return To Main Page

The Best Science Presented at the 2026 European Lung Cancer Congress

The STS 2026 Best of Lung Cancer Science special edition podcast series provides members with direct access to the most clinically relevant and practice-informing advances in lung cancer, curated and interpreted by thoracic surgeons for thoracic surgeons.

This executive summary highlights key takeaways from the 2026 European Lung Cancer Congress (ELCC), where emerging translational science, evolving surgical paradigms, and biomarker-driven decision-making were central themes shaping the future of thoracic oncology.

Join host Erin Gillaspie, MD, MPH, Associate Professor with Tenure, CHI Health, and Jonathan Spicer, MD, PhD, Associate Professor of Surgery at McGill University, as they discuss the shifting boundaries of resection, the expanding role of systemic therapy, and the growing influence of biology, AI, and real-world data on lung cancer care.

1. A Transition Point in Resectable Disease

  • Dr. Spicer emphasized that thoracic oncology is in a transition phase, with fewer large Phase 3 readouts and increasing reliance on academic, surgeon-led, and real-world studies to drive innovation.
  • ELCC 2026 highlighted a shift toward more pragmatic investigations, reflecting evolving clinical questions that are not always captured in traditional randomized trial designs.
  • He underscored that while these studies may be less visible than landmark trials, they are increasingly influential in shaping daily surgical decision-making and multidisciplinary care.

2. Redefining the Boundaries of Surgery

  • Much of the discussion centered on the interpretation of recent data in sublobar resection, particularly considering the long-term updates from Japanese trials and ongoing debate around optimal extent of resection.
  • Dr. Spicer cautioned against overinterpreting secondary or exploratory endpoints and emphasized that the 5-year outcomes remain the most robust trial endpoint for this trial.
  • He highlighted key biological considerations, including:
    • The high prevalence of driver mutations (e.g., EGFR) in certain populations, which may confound recurrence interpretation.
    • The challenge of distinguishing true recurrence vs. second primary tumors, particularly in non-smokers.
  • Overall sentiment at ELCC reflected continued support for segmentectomy in appropriately selected patients, with growing recognition that tumor biology—not just anatomic size—should guide surgical strategy.

3. The “Immunosurgeon” Era: Surgery Reframed by Systemic Therapy

  • A major theme was the evolving concept of the “immunosurgeon,” reflecting deeper integration between surgical oncology and systemic therapy.
  • Dr. Spicer noted a growing willingness among surgical leaders to reconsider previously rigid dogmas around:
    • Extent of resection.
    • Timing of surgery.
    • Integration of chemo-immunotherapy and radiation strategies.
  • Importantly, he argued that stage alone is losing predictive value in the immunotherapy era, with emerging evidence suggesting similar outcomes across stages when effective systemic therapy is used.
  • This shift reinforces a more individualized, biology-driven approach to surgical decision-making rather than strict stage-based algorithms.

4. Rethinking Resectability in the Era of Immunotherapy and ADCs

  • ELCC 2026 featured robust discussion on redefining resectability in N2 disease, particularly with the 9th edition TNM staging and increasing subclassification of nodal disease.
  • Dr. Spicer emphasized that:
    • Resectability is increasingly a dynamic, post-induction assessment, rather than a fixed pre-treatment label.
    • The key question is no longer “Can we operate?” but rather “What is the optimal local therapy after systemic response?”
  • He referenced ongoing debates in multidisciplinary forums regarding whether traditional boundaries (e.g., single-station N2 lobectomy paradigms) still apply in the era of chemo-immunotherapy and emerging antibody-drug conjugates (ADCs).
  • The overarching direction is toward adaptive, response-guided surgical planning.

5. Biomarkers, Pathologic Response, and the Limits of Imaging

  • A recurring theme was the central role of pathologic response as the strongest prognostic marker in the neoadjuvant setting.
  • Dr. Spicer highlighted that despite advances in imaging tools such as PET-based response criteria (e.g., PERCIST), imaging alone remains insufficient to reliably define complete response.
  • Key insights included:
    • Metabolic response correlates with residual viable tumor but lacks sensitivity for identifying complete response.
    • Discordance between imaging and pathology continues to challenge decision-making after neoadjuvant therapy.
  • These limitations reinforce the need for improved molecular and ctDNA-based biomarkers to better guide surgical and postoperative strategies.

6. The Expanding Role of the Microbiome, AI, and Systemic Modifiers

  • ELCC 2026 showcased emerging translational science exploring how microbiome composition may influence immunotherapy response.
  • Dr. Spicer highlighted data suggesting that specific gut flora (e.g., Bifidobacterium longum) may correlate with improved treatment response and ctDNA clearance in immunotherapy-treated patients.
  • Additional key areas of innovation included:
    • Diet and lipid metabolism as modulators of immune responsiveness.
    • AI-driven prediction models for molecular alterations from imaging data.
    • Early signals suggesting potential for non-invasive treatment strategies in select early lung cancers.
  • While still investigational, these findings point toward a future where biology and modifiable patient factors become integral to oncologic planning.

Main Points

  • Thoracic oncology is benefitting from the addition of real-world, academically driven discovery to conventional large, Phase III randomized trials.
  • Surgical decision-making will increasingly be guided by tumor biology and treatment response, not stage alone.
  • Segmentectomy remains relevant in 2026, and interpretation of long-term data requires careful attention to biology and study design.
  • Resectability in N2 disease is becoming a dynamic, post-induction, multidisciplinary decision.
  • Imaging alone remains insufficient to predict response; pathologic response remains the strongest prognostic marker, though improved biomarkers are urgently needed.
  • The microbiome, AI, and metabolic factors are emerging as important modifiers of treatment response in lung cancer.

Bottom Line

The 2026 ELCC discussions reflect a field in active transformation—where surgery is no longer defined solely by anatomy, but increasingly by biology, response to therapy, and integration with systemic and digital innovations. Thoracic surgeons are being called to play a central role in this evolution, not only as operators, but as interpreters of complex multimodal data guiding personalized cancer care.

As Dr. Spicer summarized, the next phase of progress will depend on surgeon-led academic inquiry, biomarker integration, and a willingness to rethink long-standing definitions of resectability and optimal treatment sequencing.

“We’re entering an era where lung cancer care is defined less by stage and more by biology, adaptability, and the ability to integrate new tools into surgical decision-making,” emphasized Dr. Spicer.